Oxford, UK-based Immunocore has appointed Paul Fry as its chief financial officer.
Fry has over two decades of senior management experience in the life sciences and telecommunications industries and joins the biotech from Vodafone, where he served as director of global finance operations.
Prior to this, Fry spent 25 years at GlaxoSmithKline, during which time he held a number of senior roles including head of global financial services and chief financial officer for the pharmaceutical company’s Italian business.
In his most recent role there, Fry oversaw all the financial aspects of the exchange of GSK’s oncology business for Novartis Vaccines.
Dr Eliot Forster, chief executive officer of Immunocore, said: “I am delighted that Immunocore has been able to recruit someone of the calibre of Paul Fry, who will provide leadership across our financial operations as we continue our mission to become a world leader in biotechnology.
“As Immunocore continues to grow we are continually looking for outstanding individuals such as Paul to complement our team. He joins at an exciting time for the company and we very much look forward to working with him.”